10x Genomics (TXG) reported a Q4 loss Thursday of $0.13 per diluted share, narrowing from a loss of $0.40 a year earlier.

Analysts polled by FactSet expected a loss of $0.20.

Revenue for the three months ended Dec. 31 was $166 million, up from $165 million a year earlier.

Analysts surveyed by FactSet expected $159.7 million.

For the full year 2026, the company expects revenue of $600 million to $625 million. Analysts expect $611.6 million.